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Long-acting bronchodilators in combination with inhaled corticosteroids (ICS) are recom-
mended to decrease the risk of recurrent exacerbations in patients with Global initiative for
chronic Obstructive Lung Disease (GOLD) stage 3e4 chronic obstructive pulmonary disease
(COPD). There is increasing concern about the clinical benefit and long-term safety of ICS
use in COPD patients. The WISDOM (Withdrawal of Inhaled Steroids During Optimised broncho-
dilator Management) study (NCT00975195) aims to evaluate the need for ICS use via stepwise
withdrawal of ICS in COPD patients (GOLD 3e4 with a history of at least one exacerbation dur-
ing the 12-month period prior to screening) receiving dual bronchodilation. During the 6-week
run-in period, 2456 patients receive tiotropium 18 mg once daily, salmeterol 50 mg twice daily
and fluticasone 500 mg twice daily. In a randomized, double-blind, parallel-group, active-esearch Institute at Lung Clinic Grosshansdorf, Woehrendamm 80, D-22927 Grosshansdorf, Germany.
02 8881 113.
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594 H. Magnussen et al.controlled fashion, one group of patients continues to receive tiotropium, salmeterol and flu-
ticasone, while the second group initiates stepwise withdrawal of fluticasone. The primary end
point is time to first moderate or severe exacerbation following randomized treatment over 52
weeks. Lung function, symptoms and safety are also assessed. A sub-study aims to identify sub-
populations and markers of steroid need. This study will determine the benefit of continued
ICS therapy in combination with dual long-acting bronchodilators in COPD.
ª 2014 The Authors. Published by Elsevier Ltd.Open access under CC BY-NC-ND license.Introduction and rationale
Chronic obstructive pulmonary disease (COPD) continues to
be a major cause of chronic morbidity and mortality
worldwide [1]. The principal therapeutic options include
smoking cessation, pharmacological treatment and pulmo-
nary rehabilitation, which are combined to relieve symp-
toms and reduce the risk of future events [2]. According to
current guidelines, inhaled bronchodilators, as mono-
therapy or in combination, remain the mainstay for pa-
tients with all categories of disease, with long-acting
bronchodilators being preferred over short-acting formu-
lations [2]. Both long-acting beta-2-agonists (LABAs) and
long-acting muscarinic antagonists (LAMAs) are effective in
improving airflow and decreasing lung hyperinflation, which
are important mechanisms involved in preventing exacer-
bations of COPD [3].
Combined bronchodilator treatment results in improve-
ments in lung function and patient-reported outcomes
compared to single bronchodilator therapy and could,
therefore, help prevent exacerbations in COPD patients [4].
The combination of twice-daily (BID) LABA and once-daily
(QD) LAMA, inhaled through separate devices, is an
accepted therapeutic strategy to maximize bronchodilation
and is well tolerated by the majority of patients [5].
Recently, QD dual bronchodilation with a fixed dose of the
LABA indacaterol and the LAMA glycopyrronium adminis-
tered via a single inhaler was shown to be superior in pre-
venting moderate to severe exacerbations in COPD patients
with severe to very severe airway obstruction compared to
glycopyrronium alone [6].
Guidelines for the management of patients with COPD
recommend the addition of inhaled corticosteroids (ICS) to
long-acting bronchodilator therapy in patients with severe
to very severe COPD and a history of frequent exacerba-
tions [2]. The recent update of the Global initiative for
chronic Obstructive Lung Disease (GOLD) guidelines rec-
ommends that a LAMA or ICS plus LABA should be prescribed
for patients at increased risk of exacerbation, though data
directly comparing these approaches are limited [7]. Ac-
cording to the assessment scheme suggested by GOLD, pa-
tients with an increased risk of exacerbation should be
assigned to patient groups C or D, which predominantly
include patients with GOLD stage 3 and 4 severity of airflow
obstruction [8]. However, in clinical practice, ICS are
widely prescribed for the majority of COPD patients, many
of whom who do not fall into these high-risk groups [9].
ICS are effective anti-inflammatory agents in bronchial
asthma but appear much less effective in COPD. Initial
clinical trials suggested some benefit from ICS compared to
short-acting bronchodilators in preventing exacerbations[10] but in longer-term clinical trials, such as the TORCH
(TOwards a Revolution in COPD Health) study, ICS mono-
therapy was no more effective than a twice-daily LABA and
demonstrated a worse adverse-event profile [11,12].
Re-evaluation of several clinical trials assessing the ef-
fects of ICS monotherapy in stable COPD by meta-analysis
[13], Cochrane review [14] and literature reviews [15] has
not confirmed a clinically meaningful benefit of ICS in terms
of preventing exacerbations and improving lung function
and health-related quality of life in patients with stable
COPD.
Currently, ICS are used as an adjunct to LABAs in the
prevention of exacerbations [2]. However, combination
therapy with ICS/LABA has appeared to be no more effec-
tive than monotherapy with tiotropium in preventing ex-
acerbations when compared directly in patients with severe
COPD [16], although there were fewer courses of oral cor-
ticosteroids prescribed in the ICS/LABA group. This suggests
that different therapies may prevent different types of
events. Given the potential for more effective sustained
bronchodilation with combined LABA/LAMA therapy than
with LABA alone, a comparison of this combination, with
and without added ICS, should resolve whether a benefit in
preventing exacerbations can still occur when lung function
is optimized across the full 24-h day. Although the TORCH
trial provided reassurance about the anticipated side ef-
fects associated with ICS use in general [17], an increased
incidence of pneumonia was reported among fluticasone-
treated patients [11]. This finding was confirmed in other
studies, although whether it applies to all ICS has been
disputed [18].
In a pooled analysis of two recent large clinical trials
that investigated the fixed-dose combination of vilanterol,
a QD LABA, with fluticasone furoate in COPD [19], the
observed reduction in rate of exacerbations with combined
ICS/LABA therapy compared to vilanterol monotherapy was
partly off-set by an increased frequency of investigator-
reported and radiographically confirmed pneumonias.
Given these concerns, it seems reasonable to look for a
more targeted use for ICS therapy in patients for whom the
benefits outweigh the risks. Indeed, there is accumulating
evidence that certain COPD phenotypes, characterized by
repeated exacerbations [20], inflammatory patterns [21]
and co-morbidities [22], may differ in their response to ICS.
Thus, there is a need to assess the benefit-risk profile of
ICS when added to optimized maintenance therapy with
long-acting bronchodilators in patients with stable COPD. It
is also essential to use an appropriate scheme of with-
drawing ICS in this patient population, as abrupt withdrawal
can be associated with an increased risk of exacerbations,
as highlighted by the current guidelines [2].
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for the Withdrawal of Inhaled Steroids During Optimised
bronchodilator Management (WISDOM) study
(NCT00975195), which aims to clarify the need for contin-
uous ICS use as an addition to dual bronchodilator mainte-
nance therapy and will evaluate the effect of stepwise
withdrawal of ICS therapy in patients with severe to very
severe COPD (GOLD spirometric grade 3e4). The study also
seeks to identify responder patient sub-populations, and
markers of steroid need via phenotyping and genotyping.Methods
Study design
This is a 1-year, multinational, randomized, double-blind,
parallel-group, active-controlled study (Fig. 1). Following
an initial assessment, patients enter a 6-week run-in period
in which they receive tiotropium 18 mg QD via HandiHaler,
salmeterol 50 mg BID (two actuations of 25 mg) and fluti-
casone 500 mg BID (two actuations of 250 mg), via a
metered-dose inhaler. Patients are randomized in blocks
for treatment, in a 1:1 allocation ratio, into the double-
blind phase of the trial, during which one group of pa-
tients continues to receive tiotropium 18 mg QD, salmeterol
50 mg BID and fluticasone 500 mg BID for the duration of the
52-week treatment period. The second group of patients
continues to receive tiotropium 18 mg QD and salmeterol
50 mg BID over 52 weeks but initiates a stepwise reduction
of fluticasone dose every 6 weeks from a total daily dose of
1000 mge500 mg, then to 200 mg, and finally to placebo. The
stepwise withdrawal period is followed by a stable treat-
ment phase of 40 weeks, with patients receiving tiotropium
18 mg QD, salmeterol 50 mg BID and placebo. Patients in
both groups are supplied with new medication packages
every 6 weeks to ensure blinding. During the study, patients
are permitted to use salbutamol as rescue medication andFigure 1 Study design. BID, twice-daily; ICtheophylline preparations, oral corticosteroids or antibi-
otics to treat exacerbations, as deemed medically neces-
sary. Patients withdrawing prematurely from the study are
followed up from time of withdrawal to completion of the
trial at 52 weeks.
This study is being carried out according to the Decla-
ration of Helsinki, local regulations and the International
Conference on Harmonisation Harmonised Tripartite
Guideline for Good Clinical Practice. The protocol has been
approved by the local Institutional Review Boards, Inde-
pendent Ethics Committees and the Competent Authorities
(if applicable). All patients provided written, informed
consent before the study began.Patients
Patients enrolled into the study must meet the following
inclusion criteria: age 40 years; current or ex-smokers
with a smoking history of 10 pack-years; a diagnosis of
severe to very severe COPD (i.e. a post-bronchodilator
forced expiratory volume in 1 s [FEV1] of <50% predicted
and FEV1 <70% of forced vital capacity [FVC]); a history of
at least one documented exacerbation during the 12-month
period prior to the initial screening visit. Key exclusion
criteria include: presence of a disease other than COPD
(defined as a disease or condition that, in the opinion of the
investigator, may put the patient at risk because of
participation in the study or may influence either the re-
sults of the study or the patient’s ability to participate in
the study); a current clinical diagnosis of asthma; history of
thoracotomy with pulmonary resection; unstable or life-
threatening cardiac arrhythmia; clinical diagnosis of bron-
chiectasis; a respiratory tract infection or COPD exacerba-
tion occurring within 6 weeks prior to the initial screening;
history of myocardial infarction within 3 months prior to
initial screening; or hospitalization for cardiac failure
within the past year.S, inhaled corticosteroid; QD, once-daily.
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The primary efficacy end point measured in this study is the
time to first moderate or severe on-treatment COPD exac-
erbation during the 12-month randomized period (Table 1).
A COPD exacerbation is defined as an increase or new onset
of at least two lower respiratory symptoms related to
COPD, with at least one symptom lasting a minimum of 3
days and requiring prescription of antibiotics and/or sys-
temic steroids. The start date of an exacerbation is defined
as the onset date of the first recorded COPD symptom.
Key secondary efficacy variables include the number of
moderate or severe on-treatment COPD exacerbations, the
proportion of patients experiencing at least one moderate
or severe on-treatment COPD exacerbation and the number
of hospitalizations due to on-treatment COPD exacerba-
tions (i.e. number of severe COPD exacerbations), all
assessed over the 12-month randomized period (Table 1).
Other secondary efficacy measures include in-clinic FEV1 at
weeks 0, 6, 12, 18 and 52, daily home-based spirometry
(FEV1, FVC and peak expiratory flow rate), body mass
index, exercise capacity (6-Minute Walk Test) at weeks 0,
18 and 52, dyspnoea (modified Medical Research Council
[mMRC] scale) at weeks 0, 18 and 52, the Body mass index,
airflow Obstruction, Dyspnea and Exercise capacity (BODE)
index at weeks 0, 18 and 52, Physician’s Global Evaluation
at weeks 0, 27 and 52, health-related quality of life (St.
George’s Respiratory Questionnaire [SGRQ]) at weeks 0, 27
and 52, and cough and expectoration (Cough and Sputum
Assessment Questionnaire [CASA-Q]) at weeks 0, 12, 18
and 52.Table 1 Key study end points and assessments.
End point Assessm
Primary Time to first moderate or severe
on-treatment COPD exacerbation
during the 12-month randomized period
An incr
sympto
3 day
Secondary Number of moderate to severe
on-treatment COPD exacerbations
during the 12-month randomized period
As abov
exacer
exacer
exacer
or seve
modera
Proportion of patients experiencing 1
moderate or severe on-treatment COPD
exacerbation during the 12-month
randomized period
Severity of on-treatment COPD
exacerbations during the 12-month
randomized period
Number of hospitalizations due to
COPD exacerbations over the 12-month
randomized period
Numbe
7-day g
COPD, chronic obstructive pulmonary disease.
a Shortness of breath, cough, wheezing, chest tightness, sputum pr
b Hospitalization/treatment in Urgent Care Unit, prescription of
prescribed respiratory medication (i.e. theophyllines, long-acting betSub-study
A sub-study of approximately 500 patients is being
recruited to identify sub-populations and potential markers
of steroid need. Patients enrolled into the sub-study un-
dergo high-resolution computed tomography scan prior to
randomization for quantification of emphysema and eval-
uation of bronchiectasis. In addition, body plethysmog-
raphy and a measurement of diffusing capacity for carbon
monoxide is performed. Blood samples are taken for phar-
macogenetic testing and biomarker determination (adipo-
nectin, leptin, C-reactive protein, interleukin-6,
interleukin-8, tumour necrosis factor-a, fibrinogen, soluble
interleukin adhesion molecule-1, serum amyloid A, pro-
calcitonin and B-type natriuretic peptide) at visits 3, 6 and
13. The panel of biomarkers may allow further evaluation
of the role of systemic inflammation for exacerbations,
with fibrinogen being of particular interest [23]. In addi-
tion, the cardiac biomarkers procalcitonin and B-type
natriuretic peptide may help to understand the impact of
concomitant cardiac disease on exacerbations in COPD.
Genomic DNA extraction is according to standard molecular
genetics methods and analysis by TaqMan or other stan-
dard genotyping technologies. Assessment of airway
inflammation through differential cell count is performed
at visits 3 and 13 by either induced sputum samples (inha-
lation of 0.9% saline; total inhalation time of 20 min) in
patients with FEV1 30%, or spontaneous sputum samples in
patients with FEV1 <30% using the method of selected
sputum plugs, as described elsewhere [24]. The fraction of
exhaled nitric oxide is measured at visits 3, 6 and 13.ent Time of
assessment
(weeks)
ease or new onset of 2 lower respiratory
msa related to COPD, with 1 symptom lasting
s requiring a change in treatmentb
0e52
e, applying a 7-day gap rule, e.g.
bations for which onset date of the second
bation is 7 days after the end of the first
bation are combined and considered moderate
re (if 1 of the exacerbation events is
te or severe)
0e52
r of severe exacerbations after applying a
ap rule
0e52
oduction and purulence.
antibiotics and/or systemic steroids, or significant change of
a-2-agonists, inhaled corticosteroids).
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Safety is assessed in all treated patients. All adverse
events, irrespective of causality, are monitored, and
change from baseline, date of onset, end time, intensity of
the event and treatment or action required are recorded at
each visit. Vital signs, including blood pressure and pulse
rate, are measured and recorded prior to clinic spirometry.
Clinical laboratory tests and electrocardiograms are carried
out at screening.
Statistical analysis
It is estimated that 2456 patients should be randomized
from across 200 centres to ensure that a minimum of 2234
evaluable patients complete the study. Of these 2456 pa-
tients, approximately 500 are being recruited to participate
in the sub-study. This calculation was conducted consid-
ering the primary end point (time to moderate or severe
exacerbation over the 12 months of the trial) using a 97.5%
one-tail confidence interval and 90% power, based on an
expected dropout rate of 15% per year and a standard
exponential parameter (l) of 0.077 (based on expected
median time to first moderate or severe COPD exacerbation
of 9 months, from previous studies) and assuming a non-
inferiority limit of 1.2.
This study is designed to determine non-inferiority in the
hazard of the time to first moderate or severe exacerba-
tion. The primary end point is evaluated using a one-sided
confidence interval at the 2.5% level of significance ob-
tained via Cox’s proportional hazard regression adjusting
for baseline FEV1. The null hypothesis tested is that the
hazard ratio of the mean time to exacerbation for ICS
withdrawal versus continued treatment is 1.2 and the
alternative hypothesis states that the ratio is >1.2. The
number of moderate or severe on-treatment exacerbations
is analysed using a negative binomial analysis with log
treatment exposure as off-set. Changes from baseline in-
clinic FEV1, home-based lung function (FEV1, FVC and
peak expiratory flow rate), body mass index, exercise ca-
pacity, dyspnoea (mMRC scale), BODE index, Physician’s
Global Evaluation, health-related quality of life (SGRQ) and
cough and expectoration (CASA-Q) are all analysed using a
restricted maximum-likelihood model based on a repeated-
measures approach. If a patient discontinues the trial due
to worsening of disease, his/her missing data will be
imputed by the least favourable value observed to that
time point. No formal hypothesis is being tested for the sub-
study; however, data from all end points will be summa-
rized. Safety is summarized descriptively.
Discussion
The contribution of ICS to the efficacy and long-term safety
of concomitant optimized bronchodilator therapy in COPD
remains unknown and there is concern over the benefit-risk
profile of ICS therapy itself [25]. In particular, abrupt
withdrawal of ICS at baseline or during treatment, as used
in many studies investigating the contribution of ICS, is
considered an artificial condition and may precipitate
adverse events, thereby confounding results. Thus, it isnecessary to investigate the effects of stepwise ICS with-
drawal in patients with severe and very severe COPD
receiving otherwise optimized bronchodilator therapy
[26,27].
Previous studies investigating the effects of withdrawing
ICS therapy have reported acute and persistent deteriora-
tion in lung function, dyspnoea, disturbed nights [27,28],
and an increased risk of exacerbations and shorter time to
exacerbation [29,30]. A systematic review of four trials [26]
showed that, while outcomes such as exacerbations,
health-related quality of life and lung function were
generally worse for patients discontinuing ICS therapy, the
differences compared to those who continued were small
and not always statistically significant. The contradictory
outcomes observed in these ICS-withdrawal trials may be a
direct result of some methodological issues [26,31].
In all ICS-withdrawal studies conducted to date, treat-
ment with ICS was stopped abruptly following randomiza-
tion; this abrupt withdrawal could account for the
decreased time to first exacerbation observed in some
studies [32]. Patient characteristics, disease severity and
concomitant treatments differed across studies, which may
contribute to the differences and/or inconsistencies
observed in previous ICS-withdrawal studies, especially as
the effects of ICS on exacerbations are more likely to be
seen in more severe patients.
The WISDOM study will add to the limited evidence
describing the long-term benefits of dual bronchodilation
plus ICS compared to dual bronchodilation alone. Several
considerations have been taken into account to enable the
most robust and comprehensive evaluation of this impor-
tant comparison to date.
(1) All patients will receive triple therapy for 6 weeks
before randomization, which should avoid any bias
similar to that previously reported as a result of
withdrawing treatments before randomization [31].
(2) All patients will receive stable dual bronchodilator
therapy with tiotropium QD and salmeterol BID in
accordance with current guidelines, thus potentially
reducing the risk of exacerbations following with-
drawal of ICS therapy [16].
(3) The study uses a stepwise withdrawal of ICS therapy
from the high dose (fluticasone 500 mg BID) to zero, a
method that has been successfully employed in
studies investigating the down-titration of ICS in pa-
tients with asthma [33]. Currently, there is no clear
evidence that abrupt withdrawal of ICS is safe;
stepwise withdrawal should minimize the potential
risk of rebound steroid effects, such as relative ad-
renal insufficiency, associated with abrupt with-
drawal of ICS [34]. Thus, only exacerbations
attributable to the long-term condition will be
captured, rather than those attributable to abrupt
withdrawal of high-dose ICS [34]. Blinding to the
stepwise ICS withdrawal is ensured by delivery of new
medications to all patients every 6 weeks.
(4) The primary end point of time to first exacerbation
was chosen as it is sensitive to both the occurrence of
an exacerbation and the lag time of that occurrence.
Furthermore, it is not affected by the occurrence of
multiple exacerbations in some patients and is less
598 H. Magnussen et al.likely to be affected by early discontinuation or
changes in concomitant therapies introduced after
the first exacerbation.
(5) In the sub-study, we aim to identify potential markers
of steroid responsiveness, which could help to iden-
tify subgroups of COPD patients who may benefit from
long-term steroid treatment. The stepwise with-
drawal could offer the chance to identify a minimally
effective dose of ICS in COPD.
It should be noted that inclusion criteria for the WIS-
DOM study were established based on spirometry cate-
gories from the GOLD 2010 guidelines, i.e. GOLD 3 and 4
[2]. A recent large, observational study has shown that
patients who are GOLD 3 and 4 constitute a substantial
proportion of the COPD population [20]. Although GOLD
assessments have now been updated to include risk of
exacerbations and symptoms, the new patient categories
C and D are reflected in the included study population of
patients with severe and very severe disease. Therefore,
the results from this study have the potential to guide
treatment in accordance with these latest guidelines [2].
However, the study results will be less suitable for pa-
tients with mild to moderate airflow obstruction and a
history of frequent exacerbations, as this phenotype was
not included in the study [20].
A total of 3425 patients have been screened at 209
investigator sites worldwide, with 2488 patients random-
ized to treatment. Results of this large, randomized study
will help to describe the benefit of ICS therapy to prevent
exacerbations when administered in combination with long-
acting dual bronchodilator treatment. If the overall study
population does not show a positive benefit to risk of long-
term ICS treatment, then data from the sub-study may
offer guidance to establish objective criteria for individu-
alized ICS therapy, conserving the benefit of reduced ex-
acerbations and minimizing the risk of complications, such
as pneumonia, associated with this therapy.Conflicts of interest
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